GlassScriptPhysician profile
Malithi Jayasundara
NPI 1871849976
$6,228.67
in general payments reported to CMS, 2019-2025
19 companies · $575 in 2025
The $575 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2021: $23.40 · 2022: $544 · 2023: $2,343 · 2024: $2,568 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,297.96 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,052.80 | 2021-2025 | |
| Ucb, INC. | $696.90 | 2022-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $490.97 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $329.05 | 2019-2024 | |
| Glaxosmithkline, LLC. | $321.91 | 2023-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $236.19 | 2022-2024 | Saphnelo |
| Lilly USA, LLC | $180.70 | 2023-2024 | Taltz, Zepbound |
| Horizon Therapeutics Plc | $124.96 | 2023 | Krystexxa |
| Janssen Biotech, INC. | $82.47 | 2022-2023 | Tremfya, Simponi Aria, Remicade |
| Fresenius Kabi USA, LLC | $75.37 | 2023-2024 | Idacio, Tyenne |
| Genzyme Corporation | $73.95 | 2024-2025 | |
| Radius Health, INC. | $67.22 | 2023-2024 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $51.59 | 2023-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.30 | 2023-2024 | Cyltezo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $42.21 | 2023-2024 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $34.58 | 2024 | Lupkynis |
| Janssen Pharmaceuticals, INC | $13.59 | 2022 | |
| Argenx US, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malithi Jayasundara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.